ACOG - Personalized Genomic Testing for Disease Risk

full-text ►
ACOG - Personalized Genomic Testing for Disease Risk

Number 527, June 2012

Committee on Genetics

This document reflects emerging clinical and scientific advances as of the date issued and is subject to change.
The information should not be construed as dictating an exclusive course of treatment or procedure to be followed.

PDF Format
 

Personalized Genomic Testing for Disease Risk

ABSTRACT: Advances in genetic technologies have led to the identification of hundreds of single nucleotide polymorphisms that are associated with a variety of complex diseases, including cancer, diabetes, cardiovascular disease, and Alzheimer disease. Although personalized genomic tests that provide information regarding the risk of development of multiple diseases may be important tools in the near future, their use is not recommended outside of a clinical trial until these tests are validated as clinically useful in appropriately designed prospective studies. Testing for single-gene disorders should be approached in accordance with accepted guidelines that address the evaluation and management of these specific diseases.